MedTrace Logo

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

NCT00139152 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2014-01-07

No results posted yet for this study

Summary

The purpose of this study is to study the effects of Xolair using non-invasive techniques from the expired gas of patients with moderate to severe allergic asthma.

Conditions

Interventions

DRUG

Placebo

Saline, Sub-Cuteanous (SQ)

DRUG

Xolair

Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ

Sponsors & Collaborators

Principal Investigators

  • Robert G Townley, MD · Creighton University Division of Allergy & Immunology

  • Muhammad A Pasha, M.D. · Albany Medical CollegeDivision of Allergy, Asthma, & Immunology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139152 on ClinicalTrials.gov